Compare FWRD & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | IPSC |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.5M | 405.8M |
| IPO Year | 2024 | 2021 |
| Metric | FWRD | IPSC |
|---|---|---|
| Price | $15.97 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $4.25 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.54 | ★ 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | $109,164,000.00 |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $7.86 | $0.44 |
| 52 Week High | $32.47 | $2.97 |
| Indicator | FWRD | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 46.63 |
| Support Level | $15.28 | $2.13 |
| Resistance Level | $23.55 | $2.47 |
| Average True Range (ATR) | 1.04 | 0.15 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 97.44 | 32.14 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.